BRCA1 can regulate estrogen receptor-a (ERa) activity. This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that exposure to increased estrogen or ERa collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Longer ductal extension was found in mammary glands of Brca1 f/f;MMTV-Cre mice during puberty as compared to wild-type mice. Terminal end bud differentiation was impaired in Brca1 mutant mice with preservation of prolactin-induced alveolar differentiation. Exogenous estrogen stimulated an abnormal sustained increase in mammary epithelial cell proliferation and the appearance of ERa-negative preneoplasia in postpubertal Brca1 mutant mice. Carcinogenesis was investigated using Brca1 f/f;MMTV-Cre mice hemizygous for p53. Exogenous estrogen increased the percentage of mice with multiple hyperplastic alveolar nodules. Targeted conditional ERa overexpression in mammary epithelial cells of mice that were Brca1 mutant and hemizygous for p53 increased the percentage of mice exhibiting multiple hyperplastic nodules, invasive mammary cancers and cancer multiplicity. Significantly more than half of the preneoplasia and cancers were ERa negative even as their initiation was promoted by ERa overexpression.
Introduction
Women carrying germ-line mutations of the breast cancer susceptibility gene (BRCA1) are predisposed to breast and ovarian cancers (Miki et al., 1994) . While most BRCA1 mutation-related breast cancers are estrogen receptor-a (ERa) and progesterone receptor (PR) negative (Foulkes et al., 2004) , there is a role for estrogen in early stages of cancer progression. Ovariectomy decreases breast cancer in women (Rebbeck et al., 2002) and mice (Bachelier et al., 2005) . BRCA1 represses ERa-mediated gene transcription (Fan et al., 2002) , inhibits estrogen signaling to extracellular signalregulated protein kinase and reduces cell proliferation (Razandi et al., 2004) . Tamoxifen-mediated ERa agonist activity promotes cancer development in Brca1-deficient mice (Jones et al., 2005) .
Mammary gland development is synchronized by hormones and growth factors (Fendrick et al., 1998) . Estrogen signaling through ERa promotes cellular proliferation and differentiation and stimulates terminal end bud (TEB) formation and ductal development (Bocchinfuso and Korach, 1997) . TEBs are the growing ends of mammary ducts that appear during puberty and differentiate into terminal ductal ends when pubertal mammary gland development is completed. Cell proliferation is transient in mammary epithelial cells with downregulation by negatively regulating factors including the transforming growth factor-b (TGF-b) family (Grimm and Rosen, 2006) . Placental lactogen and prolactin govern alveolar differentiation during pregnancy (Dembinski and Shiu, 1987) .
Like humans, Brca1 mutant mammary cancers that develop in mice are predominantly ERa negative (Xu et al., 1999; Brodie et al., 2001; Bachelier et al., 2005) . Human BRCA-1 mutant breast cancers frequently exhibit p53 mutation (Gudmundsdottir and Ashworth, 2006) , and p53 haploinsufficiency increases cancer incidence in mouse models. Brca1 loss in mice produces an exaggerated proliferative response to exogenous progesterone (Ma et al., 2006) and mifepristone is cancer protective (Poole et al., 2006) . Finally, Brca1-deficient mammary glands demonstrate increased ANG1 (Furuta et al., 2006) , Igf-1, Irs-1 and Igf-1r (Shukla et al., 2006) , indicating that multiple pathways implicated in breast carcinogenesis are altered by Brca1 loss.
This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that increased estrogen signaling collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Two experimental approaches were employed: exogenous estrogen exposure and a targeted conditional increase in ERa expression in mammary epithelial cells (Frech et al., 2005a, b) . Results supported the hypothesis that estrogen signaling plays a role in early stages of Brca1 mutation-related breast cancer development.
Results

Mammary glands of Brca1
f/f;MMTV-Cre mice exhibit longer ductal extension during puberty and impaired terminal end bud differentiation To test if Brca1 loss leads to an abnormal growth response to endogenous estrogen during puberty, ductal extension was analysed on mammary gland whole mounts from 3-to 6-week-old Brca1 f/f;MMTV-Cre and wild-type mice. At 3 weeks of age, ductal extension was comparable in Brca1-deficient and wild-type mice ( Figures 1a and b) ; however at age 6 weeks ductal extension was significantly longer in Brca1 f/f;MMTV-Cre as compared to wild-type mice (39.873.6 vs 17.372.9, t-test, Po0.006; Figures 1e-g ). To test if Brca1 loss compromised the differentiation response of TEBs to estrogen and progesterone, 3-week-old Brca1 f/f;MMTV-Cre and wild-type mice were exposed to continuous 17b-estradiol and progesterone for 2 weeks. Wild-type mice exhibited the expected TEB differentiation into terminal ductal ends (Figure 1d ) while TEBs from Brca1 f/f;MMTV-Cre mice did not ( Figure 1c ). In contrast, both Brca1 f/f;MMTV-Cre and wild-type mice exhibited normal alveolar differentiation (Figures 2a-d ) when exposed to prolactin in organ culture. Because increased p27 expression is found in transgenic mice expressing dominant-negative Brca1 (Deans et al., 2004) , p27, p21 and estrogen signaling-associated gene products c-myc, cyclin d1 and cyclin e were examined but no significant differences were found with Brca1 loss (Figure 3 ). In summary, Brca1 loss impaired estrogenand progesterone-induced differentiation but not the different developmental stage of prolactin-induced differentiation. p53 deficiency cooperates with estrogen stimulation in the development of hyperplastic alveolar nodules (HANs) p53 haploinsufficiency increases the percentage of Brca1 f/f;MMTV-Cre mice that develop invasive mammary adenocarcinomas (Xu et al., 1999) . HANs are noninvasive preneoplastic lesions identified in mammary gland whole mounts that reflect early events in cancer development (Heppner et al., 2000) . Estrogen exposure increased the mean number of HANs/gland and the percentage of mice with HANs similar to the effects of p53 haploinsufficiency. p53 haploinsufficiency increased the mean number of HANs from 0.370.1 in Brca1 f/f;MMTV-Cre mice to 2.070.5 in Brca1 (Arbeit et al., 1996) 1-5 months after pellet placement in 71% of the Brca1 f/f;MMTV-Cre and 1-3 months after pellet placement in 25% of the Brca1 f/f;MMTV-Cre/p53 þ /À mice. Fourteen percent of estrogen-exposed Brca1 f/f;MMTV-Cre mice and 25% of the Brca1 f/f;MMTV-Cre/p53 þ /À mice developed invasive mammary cancer similar to percentages found in untreated mice (Xu et al., 1999; Jones et al., 2005) .
Targeted ERa overexpression in mammary epithelial cells of Brca1 f/f;MMTV-Cre/p53 þ /ÀCERM mice increased the percentage of mice exhibiting multiple hyperplastic nodules and invasive multiple mammary cancers To increase estrogen signaling pathway activity specifically in mammary epithelial cells and avoid toxicity from systemic estrogen exposure, the conditional estrogen receptor a in mammory tissue (CERM) system (Frech et al., 2005a, b) was introduced into Brca1 f/f;MMTV-Cre mice to generate Brca1 f/f;MMTV-Cre/CERM and Brca1
mice demonstrated a modest nonsignificant increase in the mean number of HANs/gland (0.670.4) and HAN prevalence (40%) as compared to Brca1 f/f;MMTV-Cre mice. ERa overexpression in Brca1 f/f;MMTV-Cre/p53 þ /À/CERM mice increased mean number of HANs/gland (14.373.7, t-test, Po0.0001) and HAN prevalence (100%, w 2 , Po0.023) compared to Brca1 f/f;MMTV-Cre/p53 þ /À mice. Levels were comparable to estrogen-treated Brca1 f/f;MMTV-Cre/p53 þ /À mice. The percentage of Brca1 f/f;MMTV-Cre/p53 þ /À/CERM mice developing invasive cancer was increased (100%, w 2 , Po0.023) as compared to control Brca1 f/f;MMTV-Cre/p53 þ /À mice (53%) and mean number of palpable invasive cancers per mouse was increased to 2.670.4 in mice from 0.670.6 in (t-test, Po0.0001). The percentage of mice with multiple invasive cancers was higher in Brca1 (Figures 7c and k) , suggesting that some cells simultaneously lost full-length Brca1 and expressed ERa. However, even when ERa overexpression promoted development of mammary cancer, ERa-negative preneoplasia and cancer still emerged.
Discussion
Loss of full-length Brca1 in mammary epithelial cells in mice was associated with an abnormal response to estrogen stimulation that correlated with enhanced development of preneoplasia and invasive mammary cancer. Impaired differentiation responses during puberty and after exogenous estrogen and progesterone exposure were identified. Reduction of BRCA1 by RNA interference in a 3D culture system also results in failure of differentiation into mammary acini and increased cell proliferation (Furuta et al., 2005) . This impaired differentiation response could be one reason why pregnancy does not appear to be as protective against the development of breast cancer in women who carry a BRCA1 mutation as other populations (Cullinane et al., 2005) . Anomalous but not absent growth and differentiation responses are consistent with the fact that either loss of full-length Brca1 or BRCA1 mutation does not abort mammary gland development; instead it produces a gland that functions normally in many ways but is predisposed toward cancer development.
Estrogen stimulated sustained proliferation of ERanegative mammary epithelial cells when Brca1 function was impaired. Estrogen-induced cell proliferation is normally mediated through paracrine signaling pathways including epidermal growth factor (EGF)-and insulin growth factor (IGF)-associated pathways (Fendrick et al., 1998; Silberstein, 2001 ). BRCA1 can inhibit EGF and IGF signaling (Razandi et al., 2004) and loss of Brca1 in mouse mammary glands is associated with increased expression levels of Igf-1, Irs-1 and Igf-1r (Shukla et al., 2006) . This study showed that loss of Brca1 was associated with increased expression levels of Igfbp4 and decreased expression levels of both receptors and ligands from the inhibitory TGF-b signaling pathway. This suggests a model in which loss of Brca1 leads to increased activity of IGF signaling pathways and decreased activity of the TGF-b pathways resulting in an abnormal and sustained proliferative response to estrogen. The target cell for this proliferative response was not identified; however, it is known that over half of the adenocarcinomas that develop in this model demonstrate gene expression patterns reminiscent of human basal cell cancers, a type of human cancer that is overrepresented in BRCA1 mutation carriers (Herschkowitz et al., 2007) .
Retention of retinoid X receptor-a (RXRa) expression in the proliferating cells suggests that RXR ligands, perhaps in combination with PPARg, could be a chemopreventive approach for Brca1 mutation-related cancer through differentiation and/or reduced IGF levels (Decensi et al., 2003) .
Expression of PR is regulated by the estrogen signaling pathway in mammary tissue and mediates some estrogen-induced actions (Fendrick et al., 1998) . The PR inhibitor mifepristone is cancer protective in a different but related p53 null mouse model of Brca1 mutation-related breast cancer (Poole et al., 2006) . Mifepristone increases TGF-b1 expression, decreases cell proliferation and promotes apoptosis in ERa-and PR-positive and -negative breast cancer cell lines (El Etreby et al., 1998; Liang et al., 2003) . In tumor explants, progesterone increases IGF availability (Krzysiek et al., 2003) and mifepristone reduces this by stimulating secretion of IGFBP-3 (Milewicz et al., 2005) . It is possible that mifepristone may reduce cancer development by upregulation of inhibitory factors such as TGF-b1 and/or downregulation of stimulatory pathways including IGF. Progesterone and IGF increase ductal elongation in the mammary gland (Ruan et al., 2005) and progesterone and the PR-B isoform has been shown to increase insulin receptor substrate-2 expression (Vassen et al., 1999; Cui et al., 2003) . One can speculate that the enhanced ductal elongation observed in the Brca1-deficient mice was secondary to increased PR and IGF signaling in the pubertal mice.
Estrogen pathway stimulation was as effective as p53 haploinsufficiency in promoting the development of preneoplasia in the Brca1 f/f;MMTV-Cre mice but the combination of estrogen pathway activation with p53 haploinsufficiency in Brca1 f/f;MMTV-Cre/p53 þ /À and Brca1 f/f;MMTV-Cre/p53 þ /À/CERM mice was more potent than either intervention alone. Increasing ERa expression levels in the BRCA1 f/f;MMTV-Cre/p53 þ /À/CERM mice promoted development of both ERa-positive and -negative invasive mammary cancer. This stands in contrast to another CERM-related model in which TAg and ERa overexpression are combined to produce uniformly ERa-positive mammary cancers (Tilli et al., 2003) . The results in the Brca1 mouse model are compatible with data from human BRCA1 mutation carriers where approximately two-thirds of the breast cancers are ERa negative (Foulkes et al., 2004) .
The study suggests a model in which loss of Brca1 function results in an aberrant proliferative response to estrogen signaling leading to development of preneoplasia and cancer. In this model, p53 insufficiency is a collaborating factor. It is possible that decreased expression levels of inhibitory factors such as TGF-b family members and increased expression of stimulatory factors including the IGF signaling pathway contribute to the abnormal estrogen-induced growth response.
Materials and methods
Mice
f/f;MMTV-Cre/p53 þ /À/CERM and wild-type mice were identified using PCR. Mice were maintained under guidelines approved by the Georgetown University Animal Care and Use Committee. MMTV-Cre transgene expression initiates during embryogenesis (Wagner et al., 2001) . Subcutaneous pellet placement and ovariectomy (Raafat et al., 1999) was performed under isofluorane anesthesia. Mammary gland organ culture was carried out as described (Ginsburg and Vonderhaar, 2000) . Mice were scored as having multiple invasive cancers when more than one palpable cancer was present. Supplementary data provides experimental groups and numbers of mice.
Mammary gland whole mounts, histology and immunohistochemistry Mounted #4 mammary glands of 3-to 6-week-old mice were measured for ductal extension. In older mice, HANs were counted and prevalence calculated as the percentage of mice/ group exhibiting one or more HANs/#4 mammary gland. The other #4 mammary gland from each mouse was fixed in 10% buffered formalin, embedded in paraffin using standard techniques and 5 mm sections stained using hematoxylin and eosin (H&E) or immunohistochemical detection performed: proliferating cell nuclear antigen (PCNA) (1:100; U7032; DAKO, Carpinteria, CA, USA), ERa (1:50; IM2133; Beckman Coulter Immunotech, Miami, FL, USA), ERb (1:100; GTX70174; GeneTex Inc., San Antonio, TX, USA), PR (1:100; NCL-L-PG-AB; Novacastra, UK), RXRa (1:100; sc-553; Santa Cruz, Santa Cruz, CA, USA), smooth-muscle actin (SMA, 1:100; 1A4, MS-113-P; NeoMarkers, Fremont, CA, USA), c-Myc (1:50; sc-764; Santa Cruz), P21 (1:50; ms-387; NeoMarkers), P27 (1:50; sc-1641; Santa Cruz), cyclin D1 (1:50; sc-8396; Santa Cruz) and cyclin E (1:300; sc-481; Santa Cruz) Cre (1:400; 69050; Novagen, San Diego, CA, USA). Proliferative index and percent ERa-, ERb-and PR-positive cells were calculated. Digital photographs were taken using a Nikon Eclipse E800M microscope with DMX1200 camera (Nikon Instruments Inc., Melville, NY, USA).
Statistical analyses
Means and s.e. were analysed using Student's t-test and twoway ANOVA tests (Graphpad Software, San Diego, CA, USA). Nonparametric data were analysed using MannWhitney two-tailed and w 2 -tests (SPSS Inc., Chicago, IL, USA). Po0.05 was considered statistically significant.
